HERTFORDSHIRE, England and
PITTSBURGH, March 28, 2017 /PRNewswire/ -- Mylan N.V.
(NASDAQ, TASE: MYL) today announced the appointment of Daniel M. Gallagher as chief legal officer. He
will be joining the company on April 17,
2017.
Gallagher joins Mylan from Patomak Global Partners, a consulting
firm providing strategic advice, compliance consulting, and
litigation and regulatory enforcement services, where he was
president. From Nov. 2011 to
Oct. 2015, Gallagher served as a
commissioner of the U.S. Securities and Exchange Commission (SEC).
During his tenure at the SEC, he focused on initiatives aimed at
strengthening the U.S. capital markets and encouraging capital
formation. As commissioner, he called for reform on various
corporate governance issues, advocated for conducting a
comprehensive holistic review of equity market structure issues,
and encouraged building the Commission's fixed income market
expertise.
Before being appointed commissioner, Gallagher served on the
staff of the SEC in several capacities, including as counsel to
both SEC Commissioner Paul Atkins
and Chairman Christopher Cox,
working on matters involving the Division of Enforcement and the
Division of Trading and Markets. Gallagher served as deputy
director and co-acting director of the Division of Trading and
Markets from 2008 to 2010, where he was on the front lines of the
agency's response to the financial crisis, including representing
the Commission in the Lehman Brothers liquidation.
Mylan CEO Heather Bresch
commented, "Dan is an exceptional lawyer with a distinguished
career in both public service and the private sector. In addition
to his keen legal intellect and outstanding reputation, Dan's
extensive experience in regulatory matters, financial markets, and
corporate legal affairs and governance will add significant value
to our senior leadership team and add further depth to Mylan's
already strong legal organization. We believe that the various
transformations underway across the global healthcare industry,
most notably in the U.S., as well as Mylan's own continued
evolution into a global healthcare company, will create significant
opportunities for us going forward and Dan will be valuable in
helping us to maximize these opportunities."
Gallagher commented, "Mylan has enjoyed remarkable growth during
a very short period and has become a global powerhouse in the
generic and specialty pharmaceutical industry. I have had the
opportunity to get to know the company well over the last couple of
years and believe Mylan is uniquely positioned in the industry as a
result of its clear and compelling vision and strategy, unmatched
global assets, strong culture and unwavering commitment to doing
what is right. I am excited to join Mylan's leadership team at this
time in the company's evolution and am honored to lead the
company's world-class legal organization in support of Mylan's
future success."
In addition to his tenure in public service, Gallagher spent a
number of years in the private sector. Following law school, he
joined the Washington, D.C. law
firm Wilmer Cutler & Pickering, where he advised clients on
broker-dealer regulatory issues and represented clients in SEC and
SRO enforcement proceedings. He later returned to Wilmer (now
WilmerHale) as a partner following his staff service at the SEC.
Gallagher also served as senior vice president and general counsel
of Fiserv Securities, Inc., where he was responsible for managing
all of the firm's legal and regulatory matters.
Gallagher received his B.A. in English from Georgetown University and his J.D., magna cum
laude, from the Catholic University of
America, where he was a member of the Law Review.
Gallagher serves as non-executive director of both the Irish
Stock Exchange and Symbiont.io, and is on the advisory board of the
Drexel LeBow Center for Corporate Governance.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We market a
growing portfolio of approximately 7,500 products around the world,
including antiretroviral therapies on which approximately 50% of
people being treated for HIV/AIDS in the developing world depend.
We market our products in more than 165 countries and territories.
We are one of the world's largest producers of active
pharmaceutical ingredients. Every member of our more than
35,000-strong workforce is dedicated to creating better health for
a better world, one person at a time. Learn more at
mylan.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-names-former-sec-commissioner-daniel-gallagher-as-chief-legal-officer-300430255.html
SOURCE Mylan N.V.